Eversion Bile Duct Anastomosis: A Safe Alternative for Bile Duct Size Discrepancy in Deceased Donor Liver Transplantation

Pilar Leal‐Leyte, Greg J. McKenna, Richard M. Ruiz, Tiffany L. Anthony, Giovanna Saracino, Giuliano Testa, Goran B. Klintmalm, Peter T. W. Kim – 10 April 2018 – Bile duct size discrepancy in liver transplantation may increase the risk of biliary complications (BCs). The aim of this study was to evaluate the safety and outcomes of the eversion bile duct anastomosis technique in deceased donor liver transplantation (DDLT) with duct‐to‐duct anastomosis.

Influence of Progenitor‐Derived Regeneration Markers on Hepatitis C Virus–Related Cirrhosis Outcome (ANRS CO12 CirVir Cohort)

Dominique Wendum, Richard Layese, Nathalie Ganne‐Carrié, Valérie Bourcier, Fatiha Merabtene, Carole Cagnot, Emmanuel Sauce, Nathalie Barget, Pierre Bedossa, Benoit Terris, Janick Selves, Paulette Bioulac‐Sage, Nathalie Sturm, Christophe Sattonnet, Pierre Nahon, Françoise Roudot‐Thoraval, Marianne Ziol, for the ANRS CO12 CirVir Group – 10 April 2018 – Progenitor‐derived regeneration gives rise to the aberrant expression of biliary markers such as cytokeratin 7 (K7) and epithelial cell adhesion molecule (EpCAM) in hepatocytes.

Hepatic CREBZF couples insulin to lipogenesis by inhibiting insig activity and contributes to hepatic steatosis in diet‐induced insulin‐resistant mice

Feifei Zhang, Zhimin Hu, Gaopeng Li, Shaofeng Huo, Fengguang Ma, Aoyuan Cui, Yaqian Xue, Yamei Han, Qi Gong, Jing Gao, Hua Bian, Zhuoxian Meng, Haifu Wu, Gang Long, Yi Tan, Yan Zhang, Xu Lin, Xin Gao, Aimin Xu, Yu Li – 10 April 2018 – Insulin is critical for the regulation of de novo fatty acid synthesis, which converts glucose to lipid in the liver. However, how insulin signals are transduced into the cell and then regulate lipogenesis remains to be fully understood.

Cost‐effectiveness of antiviral treatment after resection in hepatitis B virus–related hepatocellular carcinoma patients with compensated cirrhosis

Li Xie, Juan Yin, Ruyi Xia, Guihua Zhuang – 7 April 2018 – Hepatocellular carcinoma (HCC) imposes a heavy disease burden on China due to its high morbidity and mortality. China accounts for about 50% of the total new cases and deaths worldwide. Most cases are related to hepatitis B virus (HBV) infection and are associated with cirrhosis at diagnosis. Antiviral treatment with nucleos(t)ide analogues (NAs) after resection in HBV‐related HCC can reduce recurrence and improve survival. Such treatment is in fact recommended by Chinese guidelines.

Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis

Dirk J. van der Windt, Vikas Sud, Hongji Zhang, Patrick R. Varley, Julie Goswami, Hamza O. Yazdani, Samer Tohme, Patricia Loughran, Robert M. O'Doherty, Marta I. Minervini, Hai Huang, Richard L. Simmons, Allan Tsung – 6 April 2018 – Nonalcoholic steatohepatitis (NASH) is a progressive, inflammatory form of fatty liver disease. It is the most rapidly rising risk factor for the development of hepatocellular carcinoma (HCC), which can arise in NASH with or without cirrhosis. The inflammatory signals promoting the progression of NASH to HCC remain largely unknown.

Subscribe to